Arrowhead Research (ARWR) PT Lowered to $5 at Jefferies Following Clinical Hold

November 10, 2016 7:54 AM EST
Get Alerts ARWR Hot Sheet
Price: $1.38 -2.82%

Rating Summary:
    1 Buy, 7 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 28
Trade ARWR Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst Eun Yang reiterated a Hold rating and cut his price target on Arrowhead Research (NASDAQ: ARWR) to $5.00 (from $6.50) following clinical hold.

Yang commented, "FDA's decision to place a clinical hold on Heparc-2004 trial of ARC-520 based on death in non-human primate study came as a surprise. While ARWR does not expect the hold to delay progress of any of its programs, until proven it's safe, we take a cautious view, adjusting PT to $5 from $6.50."

For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.

Shares of Arrowhead Research closed at $4.20 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment